EBS
Income statement / Annual
Last year (2024), Emergent BioSolutions Inc.'s total revenue was $1.01 B,
a decrease of 3.40% from the previous year.
In 2024, Emergent BioSolutions Inc.'s net income was -$190.60 M.
See Emergent BioSolutions Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.01 B |
$1.05 B |
$1.12 B |
$1.79 B |
$1.56 B |
$1.11 B |
$782.40 M |
$560.87 M |
$488.78 M |
$522.79 M |
| Cost of Revenue |
$1.00
|
$705.40 M
|
$693.70 M
|
$757.50 M
|
$524.00 M
|
$433.50 M
|
$322.30 M
|
$195.71 M
|
$131.28 M
|
$124.30 M
|
| Gross Profit |
$1.01 B
|
$343.90 M
|
$427.20 M
|
$1.04 B
|
$1.03 B
|
$672.50 M
|
$460.10 M
|
$365.17 M
|
$357.50 M
|
$398.49 M
|
| Gross Profit Ratio |
1
|
0.33
|
0.38
|
0.58
|
0.66
|
0.61
|
0.59
|
0.65
|
0.73
|
0.76
|
| Research and Development Expenses |
$70.70 M
|
$111.40 M
|
$193.00 M
|
$234.00 M
|
$234.50 M
|
$226.20 M
|
$142.80 M
|
$97.38 M
|
$108.29 M
|
$154.00 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$202.50 M
|
$143.50 M
|
$143.69 M
|
$148.46 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$308.00 M
|
$368.40 M
|
$340.30 M
|
$348.40 M
|
$303.30 M
|
$273.50 M
|
$202.50 M
|
$143.50 M
|
$143.69 M
|
$148.46 M
|
| Other Expenses |
$773.60 M
|
$564.20 M
|
$59.90 M
|
$58.50 M
|
$59.80 M
|
$58.70 M
|
$1.60 M
|
-$815,000.00
|
$263,000.00
|
-$319,000.00
|
| Operating Expenses |
$1.15 B
|
$1.04 B
|
$593.20 M
|
$640.90 M
|
$597.60 M
|
$558.40 M
|
$370.30 M
|
$240.88 M
|
$251.98 M
|
$302.46 M
|
| Cost And Expenses |
$1.15 B
|
$1.78 B
|
$1.29 B
|
$1.40 B
|
$1.12 B
|
$991.90 M
|
$692.60 M
|
$436.59 M
|
$383.26 M
|
$426.75 M
|
| Interest Income |
$0.00
|
$0.00
|
$37.30 M
|
$34.50 M
|
$31.30 M
|
$38.40 M
|
$0.00
|
$1.75 M
|
$1.05 M
|
$572,000.00
|
| Interest Expense |
$71.00 M
|
$87.90 M
|
$37.30 M
|
$34.50 M
|
$31.30 M
|
$38.40 M
|
$9.90 M
|
$6.59 M
|
$7.62 M
|
$6.52 M
|
| Depreciation & Amortization |
$108.80 M
|
$125.10 M
|
$148.90 M
|
$126.30 M
|
$114.40 M
|
$110.90 M
|
$61.30 M
|
$40.80 M
|
$38.23 M
|
$35.34 M
|
| EBITDA |
$36.90 M |
-$505.30 M |
-$32.90 M |
$458.20 M |
$549.00 M |
$227.30 M |
$152.70 M |
$158.13 M |
$145.07 M |
$177.57 M |
| EBITDA Ratio |
0.04
|
-0.48
|
-0.03
|
0.29
|
0.36
|
0.2
|
0.15
|
0.22
|
0.22
|
0.25
|
| Operating Income Ratio |
-0.11
|
-0.69
|
-0.15
|
0.2
|
0.28
|
0.1
|
0.11
|
0.22
|
0.22
|
0.18
|
| Total Other Income/Expenses Net |
-$34.20 M
|
-$4.80 M
|
-$53.00 M
|
-$38.20 M
|
-$26.60 M
|
-$36.70 M
|
-$8.30 M
|
-$5.70 M
|
-$6.30 M
|
-$5.80 M
|
| Income Before Tax |
-$142.90 M
|
-$731.20 M
|
-$221.70 M
|
$314.40 M
|
$407.20 M
|
$77.40 M
|
$81.50 M
|
$118.63 M
|
$99.22 M
|
$89.77 M
|
| Income Before Tax Ratio |
-0.14
|
-0.7
|
-0.2
|
0.18
|
0.26
|
0.07
|
0.1
|
0.21
|
0.2
|
0.17
|
| Income Tax Expense |
$47.70 M
|
$29.30 M
|
$2.10 M
|
$83.50 M
|
$102.10 M
|
$22.90 M
|
$18.80 M
|
$36.04 M
|
$36.70 M
|
$26.90 M
|
| Net Income |
-$190.60 M
|
-$760.50 M
|
-$223.80 M
|
$219.50 M
|
$305.80 M
|
$54.50 M
|
$62.70 M
|
$82.59 M
|
$51.78 M
|
$62.87 M
|
| Net Income Ratio |
-0.19
|
-0.72
|
-0.2
|
0.12
|
0.2
|
0.05
|
0.08
|
0.15
|
0.11
|
0.12
|
| EPS |
-3.6 |
-14.85 |
-4.47 |
4.1 |
5.79 |
1.06 |
1.25 |
1.98 |
1.29 |
1.63 |
| EPS Diluted |
-3.6 |
-14.85 |
-4.47 |
4.06 |
5.67 |
1.04 |
1.22 |
1.71 |
1.13 |
1.41 |
| Weighted Average Shares Out |
$53.00 M
|
$51.20 M
|
$50.10 M
|
$53.50 M
|
$52.70 M
|
$51.50 M
|
$50.10 M
|
$41.82 M
|
$40.18 M
|
$38.60 M
|
| Weighted Average Shares Out Diluted |
$53.00 M
|
$51.20 M
|
$50.10 M
|
$54.10 M
|
$53.80 M
|
$52.40 M
|
$51.40 M
|
$50.33 M
|
$49.34 M
|
$47.26 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
